Inventor · disambiguated record
Henryk T. Dudek
Also filed as: DUDEK HENRYK · DUDEK HENRYK T
61 granted patents·28 pending applications·336 citations·filing 1999–2025
98Inventor score
Files withDICERNA PHARMACEUTICALS INC64NOVO NORDISK AS7CURIS INC6BOEHRINGER INGELHEIM INT3ASTRAZENECA IRELAND LTD2
Top patents by PatentIndex Score
89 records- 0196US10370655B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2016·Granted Aug 6, 2019·14 cites·22 claims
- 0296US9458457B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Oct 4, 2016·19 cites·52 claims
- 0393US11661604B2Methods and compositions for inhibiting expression of LDHADICERNA PHARMACEUTICALS INC·Filed 2020·Granted May 30, 2023·3 cites·20 claims
- 0493US10036017B2Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2016·Granted Jul 31, 2018·5 cites·24 claims
- 0593US9701966B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Jul 11, 2017·12 cites·68 claims
- 0692US10351854B2Therapeutic inhibition of lactate dehydrogenase and agents thereforDICERNA PHARMACEUTICALS INC·Filed 2015·Granted Jul 16, 2019·9 cites·34 claims
- 0792US10150965B2Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Dec 11, 2018·6 cites·24 claims
- 0892US9828606B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2017·Granted Nov 28, 2017·7 cites·38 claims
- 0992US8815825B2Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2012·Granted Aug 26, 2014·12 cites·45 claims
- 1092US6291516B1Regulators of the hedgehog pathway, compositions and uses related theretoCURIS INC·Filed 1999·Granted Sep 18, 2001·105 cites·16 claims
- 1191US11060093B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2019·Granted Jul 13, 2021·2 cites·20 claims
- 1291US10676742B2Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2018·Granted Jun 9, 2020·3 cites·30 claims
- 1391US8357368B2Methods of treating pancreatic or liver cancer using hedgehog antagonistsCURIS INC·Filed 2010·Granted Jan 22, 2013·24 cites·24 claims
- 1491US6686388B2Regulators of the hedgehog pathway, compositions and uses related theretoCURIS INC·Filed 2001·Granted Feb 3, 2004·48 cites·14 claims
- 1590US11053502B1Therapeutic inhibition of lactate dehydrogenase and agents thereforDICERNA PHARMACEUTICALS INC·Filed 2020·Granted Jul 6, 2021·2 cites·30 claims
- 1690US10738311B2Therapeutic inhibition of lactate dehydrogenase and agents thereforDICERNA PHARMACEUTICALS INC·Filed 2019·Granted Aug 11, 2020·3 cites·39 claims
- 1789US11773390B2Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2020·Granted Oct 3, 2023·1 cites·20 claims
- 1888US11952574B2Compositions and methods for inhibiting transmembrane serine protease 6 (TMPRSS6) expressionNOVO NORDISK AS·Filed 2023·Granted Apr 9, 2024·1 cites·28 claims
- 1988US11655473B2Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (MARC1) expressionNOVO NORDISK AS·Filed 2022·Granted May 23, 2023·2 cites·27 claims
- 2088US10954517B2Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2018·Granted Mar 23, 2021·2 cites·20 claims
- 2188US8927515B2Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2012·Granted Jan 6, 2015·9 cites·42 claims
- 2287US12252691B2Compositions and methods for inhibiting LPA expressionDICERNA PHARMACEUTICALS INC·Filed 2024·Granted Mar 18, 2025·0 cites·4 claims
- 2387US10435692B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2017·Granted Oct 8, 2019·3 cites·20 claims
- 2486US9732347B2Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Aug 15, 2017·6 cites·38 claims
- 2585US10689647B2Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2016·Granted Jun 23, 2020·2 cites·32 claims
- 2685US10612023B2Methods and compositions for the specific inhibition of β-catenin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2018·Granted Apr 7, 2020·1 cites·21 claims
- 2785US10487330B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2019·Granted Nov 26, 2019·2 cites·30 claims
- 2885US10465195B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2019·Granted Nov 5, 2019·2 cites·28 claims
- 2984US11851658B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2022·Granted Dec 26, 2023·0 cites·17 claims
- 3084US7708998B2Methods of inhibiting unwanted cell proliferation using hedgehog antagonistsCURIS INC·Filed 2003·Granted May 4, 2010·11 cites·63 claims
- 3183US11912996B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2022·Granted Feb 27, 2024·0 cites·24 claims
- 3282US9428752B2Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2015·Granted Aug 30, 2016·2 cites·14 claims
- 3382US9243244B2Methods and compositions for the specific inhibition of beta-catenin by double stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Jan 26, 2016·3 cites·12 claims
- 3482US2023069235A1Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rnaDICERNA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3581US11459566B1Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2021·Granted Oct 4, 2022·0 cites·25 claims
- 3681US11408002B1Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2021·Granted Aug 9, 2022·0 cites·25 claims
- 3781US11312960B1Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2021·Granted Apr 26, 2022·0 cites·19 claims
- 3881US11312961B1Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2021·Granted Apr 26, 2022·0 cites·26 claims
- 3980US11572562B2Compositions and methods for inhibiting GYS2 expressionDICERNA PHARMACEUTICALS INC·Filed 2019·Granted Feb 7, 2023·1 cites·35 claims
- 4080US11566248B2PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditionsDICERNA PHARMACEUTICALS INC·Filed 2019·Granted Jan 31, 2023·1 cites·20 claims
- 4180US11286488B2Methods and compositions for inhibiting expression of LDHADICERNA PHARMACEUTICALS INC·Filed 2018·Granted Mar 29, 2022·1 cites·25 claims
- 4279US11873493B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2021·Granted Jan 16, 2024·0 cites·20 claims
- 4379US10844381B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2019·Granted Nov 24, 2020·0 cites·22 claims
- 4479US2025283091A1Methods and compositions for inhibiting expression of ldhaNOVO NORDISK HEALTHCARE AG·Filed 2025·Application pending·0 cites
- 4578US9562228B2Methods and compositions for the specific inhibition of MYC by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2013·Granted Feb 7, 2017·2 cites·64 claims
- 4678US9365850B2Methods and compositions for the specific inhibition of MYC by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2013·Granted Jun 14, 2016·2 cites·51 claims
- 4778US2024401059A1Compositions and methods for modulating pnpla3 expressionDICERNA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4877US12503701B2Compositions and methods for inhibiting transmembrane serine protease 6 (TMPRSS6) expressionNOVO NORDISK AS·Filed 2024·Granted Dec 23, 2025·0 cites·22 claims
- 4977US11208658B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2020·Granted Dec 28, 2021·0 cites·29 claims
- 5077US2024182901A1Methods and compositions for inhibiting expression of ldhaNOVO NORDISK HEALTHCARE AG·Filed 2022·Application pending·0 cites
Showing the top 50 of 89 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Henryk T. Dudek files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →